Assessing HER2 amplification in breast cancer: findings from the Australian In Situ Hybridization Program
Breast Cancer Research and Treatment, 06/15/2012
Bilous M et al. – The findings demonstrate the successful implementation of a regulated, national program that continues to collect data on human epidermal growth factor receptor 2 (HER2) status. The results also highlight the differences in immunohistochemistry (IHC) interpretation between local laboratories and a central, more experienced, laboratory. This model could be used to establish future biomarker–testing programs in other countries.
